Firas Petros, MD
Urology · Toledo, OHNPI 1891096111
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by EMD Serono, Inc. at 52.4% of the total. Reporting peaked in 2023 at $7,692 and has fallen 84.9% since, to $1,164 in 2025.
Across 189 payments — averaging $68.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$7K
- Astellas Pharma US Inc$1K
- Johnson & Johnson$453
- Myovant Sciences Inc.$411
- Intuitive Surgical$403
- Progenics Pharmaceuticals, Inc.$342
- plus $3K from 28 others
Across 62 payments — averaging $1845.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- QED Therapeutics, Inc.$70K
- Sumitomo Pharma America, Inc.$45K
What the payments were for
- Consulting fees$6,75052%
- Travel & lodging$2922%
- Food & beverage$5,23641%
- Education$5985%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 1 | $6,750 |
| Astellas Pharma US Inc | 29 | $1,085 |
| Johnson & Johnson(2 entities) | 10 | $453 |
| Myovant Sciences Inc. | 21 | $411 |
| Intuitive Surgical | 5 | $403 |
| Progenics Pharmaceuticals, Inc. | 12 | $342 |
| Blue Earth Diagnostics | 15 | $318 |
| Boston Scientific | 6 | $278 |
| Sumitomo Pharma America, Inc. | 11 | $265 |
| Pfizer | 10 | $249 |
| Ferring Pharmaceuticals Inc. | 8 | $227 |
| Dendreon Pharmaceuticals LLC | 7 | $227 |
| Olympus America Inc. | 3 | $226 |
| Merck | 8 | $206 |
| Immunitybio, Inc. | 5 | $153 |
| Telix Pharmaceuticals | 3 | $144 |
| Urogen Pharma, Inc. | 7 | $136 |
| Bayer | 8 | $136 |
| Coloplast | 2 | $128 |
| Angiodynamics, Inc. | 1 | $114 |
| Cook Medical LLC | 1 | $102 |
| KARL Storz Endoscopy-america | 1 | $95 |
| Axonics, Inc. | 1 | $72 |
| Novartis | 3 | $67 |
| Conmed Corporation | 1 | $60 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Antares Pharma, Inc. | 1 | $37 |
| Janssen Scientific Affairs, LLC | 1 | $31 |
| Sanofi | 1 | $25 |
| AstraZeneca | 1 | $24 |
| Rochester Medical Corporation | 1 | $24 |
| Teleflex LLC | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$285
- Erleada$125
- AKEEGA$125
- PYLARIFY$118
- Nanoknife$114
- RYBREVANT$111
- CARVYKTI$111
- AdVance XP$106
- XTANDI$104
- iTIND System$103
- Soltive$103
- LITHO 150$102
How this compares
$12,877 in reported general payments places this provider in the 85th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 17 | $238,557 |
| ErleadaApalutamide | 13 | $193,018 |
| Abiraterone Acetate | 82 | $113,207 |
| OrgovyxRelugolix | 15 | $39,006 |
| MyrbetriqMirabegron | 47 | $26,894 |
| Potassium Citrate ErPotassium Citrate | 35 | $4,578 |
| Tamsulosin Hcl | 131 | $1,699 |
| Oxybutynin Chloride ErOxybutynin Chloride | 68 | $1,481 |
| Trospium Chloride | 12 | $1,374 |
| Tadalafil | 14 | $915 |
| Finasteride | 27 | $311 |
| Prednisone | 65 | $219 |
| Ciprofloxacin Hcl | 57 | $194 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $40 |
| Amoxicillin | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,085 | $265,45164 claims |
| Johnson & JohnsonErleada | $453 | $193,01813 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $31 | $113,20782 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $265 | $39,00615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 485 urology providers in Ohio.
Other urology in Toledo
- Lawrence GervasiMiddleburg Heights$1.1M
- Howard GoldmanCleveland$721K
- Ronney AbazaWorthington$374K
- Sriharan SivalingamCleveland$276K
- Sandip VasavadaCleveland$263K
- Jihad KaoukCleveland$234K
- Benjamin MartinGahanna$205K
- Ruben OlivaresCleveland$184K
- Abhinav SidanaCincinnati$174K
- Raymond RackleyCleveland$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.